Compare VTGN & NEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTGN | NEON |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 27.5M |
| IPO Year | 2014 | 1994 |
| Metric | VTGN | NEON |
|---|---|---|
| Price | $0.27 | $0.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.8M | 104.6K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.88 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,108,000.00 |
| Revenue This Year | $124.49 | $72.74 |
| Revenue Next Year | $353.99 | $28.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.72 |
| 52 Week High | $5.14 | $26.95 |
| Indicator | VTGN | NEON |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 47.22 |
| Support Level | $0.21 | $0.75 |
| Resistance Level | $0.32 | $0.91 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.89 | 52.67 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.